Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis:
Unattained Target in Standard Antibiotic Dosing: A Case Study

J 2025

Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study

MARACZEK MARKOVÁ, Eliška; Nela ŠŤASTNÁ; Libor FILA a Kateřina HORSKÁ

Základní údaje

Originální název

Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study

Autoři

MARACZEK MARKOVÁ, Eliška; Nela ŠŤASTNÁ; Libor FILA a Kateřina HORSKÁ

Vydání

THERAPEUTIC DRUG MONITORING, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2025, 0163-4356

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14160/25:00141662

Organizační jednotka

Farmaceutická fakulta

Klíčová slova anglicky

cystic fibrosis; therapeutic drug monitoring; meropenem; piperacillin

Štítky

14110215, podil, rivok, ÚFTo

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2026 15:41, Mgr. Irena Doubková

Anotace

V originále

Acute exacerbations of cystic fibrosis (CF) diminish quality of life and, if inadequately treated, can be life-threatening. The pathophysiological alterations associated with CF result in modified antibiotic pharmacokinetics. Moreover, the viscous mucus in the lungs limits pathogen exposure to drugs, rendering successful antibiotic treatment challenging. A 23-year-old female patient with CF was repeatedly admitted for intravenous antibiotic therapy for acute exacerbation of Pseudomonas aeruginosa infection. In the context of altered pharmacokinetics in CF, therapeutic drug monitoring of meropenem and piperacillin revealed consistently low plasma levels of both drugs. Targeted plasma levels were ultimately achieved through continuous high-dose infusions, based on therapeutic drug monitoring and subsequent dose adjustments

Návaznosti

MUNI/A/1433/2023, interní kód MU

Název: Terapeutické monitorování léčiv - nástroj k optimalizaci antibiotické a antimykotické léčby

Investor: Masarykova univerzita, Terapeutické monitorování léčiv - nástroj k optimalizaci antibiotické a antimykotické léčby

Citovat

MARACZEK MARKOVÁ, Eliška; Nela ŠŤASTNÁ; Libor FILA a Kateřina HORSKÁ. Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study. THERAPEUTIC DRUG MONITORING. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2025, roč. 47, č. 5, s. 580-583. ISSN 0163-4356. Dostupné z: https://doi.org/10.1097/FTD.0000000000001340.

@article{2509477,
   author = {Maraczek Marková, Eliška and Šťastná, Nela and Fila, Libor and Horská, Kateřina},
   article_location = {PHILADELPHIA},
   article_number = {5},
   doi = {https://doi.org/10.1097/FTD.0000000000001340},
   keywords = {cystic fibrosis; therapeutic drug monitoring; meropenem; piperacillin},
   language = {eng},
   issn = {0163-4356},
   journal = {THERAPEUTIC DRUG MONITORING},
   title = {Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study},
   url = {https://journals.lww.com/drug-monitoring/fulltext/2025/10000/therapeutic_drug_monitoring_of_beta_lactams_in.3.aspx},
   volume = {47},
   year = {2025}
}

TY  - JOUR
ID  - 2509477
AU  - Maraczek Marková, Eliška - Šťastná, Nela - Fila, Libor - Horská, Kateřina
PY  - 2025
TI  - Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study
JF  - THERAPEUTIC DRUG MONITORING
VL  - 47
IS  - 5
SP  - 580-583
EP  - 580-583
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 01634356
KW  - cystic fibrosis
KW  - therapeutic drug monitoring
KW  - meropenem
KW  - piperacillin
UR  - https://journals.lww.com/drug-monitoring/fulltext/2025/10000/therapeutic_drug_monitoring_of_beta_lactams_in.3.aspx
N2  - Acute exacerbations of cystic fibrosis (CF) diminish quality of life and, if inadequately treated, can be life-threatening. The pathophysiological alterations associated with CF result in modified antibiotic pharmacokinetics. Moreover, the viscous mucus in the lungs limits pathogen exposure to drugs, rendering successful antibiotic treatment challenging. A 23-year-old female patient with CF was repeatedly admitted for intravenous antibiotic therapy for acute exacerbation of Pseudomonas aeruginosa infection. In the context of altered pharmacokinetics in CF, therapeutic drug monitoring of meropenem and piperacillin revealed consistently low plasma levels of both drugs. Targeted plasma levels were ultimately achieved through continuous high-dose infusions, based on therapeutic drug monitoring and subsequent dose adjustments
ER  -

MARACZEK MARKOVÁ, Eliška; Nela ŠŤASTNÁ; Libor FILA a Kateřina HORSKÁ. Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing: A Case Study. \textit{THERAPEUTIC DRUG MONITORING}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2025, roč.~47, č.~5, s.~580-583. ISSN~0163-4356. Dostupné z: https://doi.org/10.1097/FTD.0000000000001340.

Přehled o publikaci